Rep. Maria Elvira Buys Biogen (BIIB) Stock

Representative Maria Elvira recently disclosed a purchase of Biogen Inc. (BIIB) stock valued between $50,001 and $100,000. According to a periodic transaction report filed under the STOCK Act, the trade took place on May 11, 2026, and was officially reported about a month later on June 9, 2026. This disclosure follows previous reports of the congresswoman selling smaller amounts of the same stock later in the year, showing active management of her position in the biotech firm.

Biogen shares were trading at $198.64 on Saturday. The stock has stayed within a 52-week range of $135.39 to $225.80. Investors often watch where a stock sits relative to its historical averages; currently, the price is holding above its 200-day moving average of $193.04, though it has dipped below the 50-day average of $210.96. The company carries a market value of about $32.37 billion and trades at a forward P/E ratio of 13.25, which measures the stock price against its expected earnings over the next year.

Recent Earnings Performance

Biogen reported revenue of $10.03 billion in its latest financial cycle, representing a growth rate of 3.4%. The company generated earnings per share (EPS) of $5.62, with a net profit margin of 8.3%. These results come as the firm continues to transition its portfolio toward newer treatments for Alzheimer's and rare diseases. The next time the company will update the public on its financial health is scheduled for October 28, 2026.

Analysts Set New Price Targets

Several research firms have updated their views on Biogen throughout late 2026. On October 12, JP Morgan upgraded the stock to an Overweight rating and set a $300 price target. Earlier that month, on October 9, UBS maintained a Buy rating and lifted its target to $270. RBC Capital also kept an Outperform rating on October 8, though it slightly adjusted its target to $256. Not everyone is as optimistic; HSBC maintained a Reduce rating on September 10 with a target of $175. Currently, 31 analysts follow the stock, and the consensus suggests a buy with an average price target of $238.18.

Developing Specialized Therapies

Biogen is a biotechnology company based in Cambridge, Massachusetts, that focuses on discovering and delivering treatments for neurological and neurodegenerative diseases. While it is well known for its multiple sclerosis drugs like Tecfidera and Tysabri, the company has recently shifted its focus toward new therapies for Alzheimer’s disease, such as Leqembi, and treatments for postpartum depression. Its business model relies heavily on complex scientific collaborations and licensing deals to bring these specialized medicines to market.

Watching the Next Disclosure

Investors will likely watch for further transaction reports to see if other members of Congress are trading in the healthcare sector. Because these STOCK Act filings are disclosed after the trade has already happened, they show what a politician did in the past rather than what they are doing today. The next major milestone for the company will be its late October earnings call, which should provide more clarity on how its newer product launches are contributing to the bottom line.